| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H14IN3O3 |
| Molecular Weight | 407.1956 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)C1=C2CN(C)C(=O)C3=C(C=CC=C3[123I])N2C=N1
InChI
InChIKey=FRIZVHMAECRUBR-KIWWSDKQSA-N
InChI=1S/C15H14IN3O3/c1-3-22-15(21)13-11-7-18(2)14(20)12-9(16)5-4-6-10(12)19(11)8-17-13/h4-6,8H,3,7H2,1-2H3/i16-4
| Molecular Formula | C15H14IN3O3 |
| Molecular Weight | 407.1956 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
[123I]Iomazenil ([123I] IMZ) is a ligand displaying high affinity for central-type benzodiazepine receptors. It is a useful marker of neuronal viability. [123I]IMZ has been successfully used as a probe for single photon emission computed tomography (SPECT) in numerous clinical studies of diseases and also itcan be used to image epileptic seizure foci. 123I-iomazenil is rapidly metabolized and more than 90% of the administrated radioactivity was excreted within the first 24 hr. Dominant metabolites were acid metabolite (R-COOH), glucuronide of the acid (R-COOH-Glc) and free iodide (I-). Metabolites of 123I-iomazenil do not cross the blood-brain barrier. [123I]IMZ is readily available commercially.
